OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma

June 22nd 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.

Dr. Sohal on Perioperative mFOLFIRINOX in Pancreatic Adenocarcinoma

June 22nd 2017

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

Dr. Ferris on Combining Immunotherapy and Radiation Therapy in Head and Neck Cancer

June 22nd 2017

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the rationale for combining radiation therapy with immunotherapy for the treatment of patients with head and neck cancer.

Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer

June 22nd 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the May 2017 FDA approval of pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Dr. Uzzo on Trials Investigating Immunotherapy in Kidney Cancer

June 22nd 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.

Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC

June 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

Dr. Verschraegen on Combining Immunotherapy Agents in Lung Cancer

June 22nd 2017

Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.

Dr. Black on Sequencing of Immunotherapy in Bladder Cancer

June 21st 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses sequencing of immunotherapy for patients with bladder cancer.

Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval

June 21st 2017

Leena Gandhi, MD, PhD, associate professor, Department of Medicine, director, Thoracic Medical Oncology Program, discusses the findings of cohort G of the KEYNOTE-021 trial that explored the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed for patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

Dr. Saab on Napabucasin (BBI-608) in Colorectal Cancer Treatment

June 20th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer

June 20th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.

Dr. Machiels on Toxicities with Pembrolizumab for Head and Neck Cancer

June 20th 2017

Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses toxicities with pembrolizumab (Keytruda) in combination with chemoradiation for patients with head and neck cancer.

Dr. Lee on Combining Anti-PD-L1 to Standard of Care for Head and Neck Cancer

June 20th 2017

Nancy Y. Lee, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the combination of a PD-L1 inhibitor to the standard of care for patients with head and neck cancer.

Dr. Chi on Androgen Deprivation Therapy for High-Risk Metastatic Hormone-Naive Prostate Cancer

June 20th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20th 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Dr. Hellmann on Nivolumab in Combination with Ipilimumab for Small Cell Lung Cancer

June 20th 2017

Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

Dr. Diaz on Pembrolizumab for CRC

June 20th 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer

June 20th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses preventing brain metastases in patients with HER2-positive breast cancer.

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer

June 19th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma

June 19th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.